Log in

Relevant bibliographies by topics / Heart Diseases Treatment Victoria / Journal articles

Journal articles on the topic 'Heart Diseases Treatment Victoria'

To see the other types of publications on this topic, follow the link: Heart Diseases Treatment Victoria.

Author: Grafiati

Published: 10 December 2022

Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Heart Diseases Treatment Victoria.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Funder, Jordan L., Kelly-Ann Bowles, and Linda J. Ross. "Diagnostic ability of a computer algorithm to identify prehospital STEMI." Journal of Paramedic Practice 14, no. 9 (September 2, 2022): 366–72. http://dx.doi.org/10.12968/jpar.2022.14.9.366.

Full text

Abstract:

Background: Acute myocardial infarction (AMI) accounts for 43% of deaths related to ischaemic heart disease, with ST-segment elevation myocardial infarction (STEMI) accounting for 25%–40% of all AMI presentations. Given the impact of these diseases, there is a strong prehospital focus on early identification, treatment and transport of patients with acute coronary syndrome. The main aim of the STEMI system of care is to reduce the time to reperfusion of the myocardium, thereby improving morbidity and mortality rates. Therefore, the identification of STEMI by paramedics can have a dramatic effect on patients' long-term health outcomes. Ambulance Victoria paramedics play a crucial role in the care provided to AMI patients across the state, with the assistance of a computer-automated interpretation of 12-lead electrocardiograms (ECGs) to aid STEMI identification. Objectives: This study's objective is to analyse the diagnostic capability of the computer-automated interpretation to diagnose STEMI in the out-of-hospital setting. Methods: Quantitative data from January 2018 to December 2019 was sourced from the Victorian Ambulance STEMI Quality Initiative. These data were periodically matched with hospital outcome and diagnosis data from the Victorian Cardiac Outcomes Registry to compare provisional paramedic diagnoses with the final hospital diagnoses. Results: Of the 5269 cases of suspected STEMI, 765 (14.5%) could be matched with outcome data. Of these 765 cases, 88.9% were correctly identified as STEMI. The remaining 10% were categorised as either non-STEMI or unstable angina. No data were available for 1.1%. Conclusions: The diagnostic capability of the Zoll Inovise 12L interpretive algorithm to diagnose STEMI in the out-of-hospital setting appears safe and feasible. However, because of limited data matching paramedic findings with patient outcomes in hospital, no hard conclusions can be drawn. Furthermore, there is no way to ascertain how many false positives the Zoll monitor is interpreting. Further investigation is required to assess the true diagnostic capability of the Zoll Inovise 12L interpretive algorithm.

APA, Harvard, Vancouver, ISO, and other styles

2

Jones, Julia L., Natalie G. Lumsden, Koen Simons, Anis Ta'eed, Maximilian P. de Courten, Tissa Wijeratne, Nicholas Cox, et al. "Using electronic medical record data to assess chronic kidney disease, type 2 diabetes and cardiovascular disease testing, recognition and management as documented in Australian general practice: a cross-sectional analysis." Family Medicine and Community Health 10, no. 1 (February 2022): e001006. http://dx.doi.org/10.1136/fmch-2021-001006.

Full text

Abstract:

ObjectivesTo evaluate the capacity of general practice (GP) electronic medical record (EMR) data to assess risk factor detection, disease diagnostic testing, diagnosis, monitoring and pharmacotherapy for the interrelated chronic vascular diseases—chronic kidney disease (CKD), type 2 diabetes (T2D) and cardiovascular disease.DesignCross-sectional analysis of data extracted on a single date for each practice between 12 April 2017 and 18 April 2017 incorporating data from any time on or before data extraction, using baseline data from the Chronic Disease early detection and Improved Management in PrimAry Care ProjecT. Deidentified data were extracted from GP EMRs using the Pen Computer Systems Clinical Audit Tool and descriptive statistics used to describe the study population.SettingEight GPs in Victoria, Australia.ParticipantsPatients were ≥18 years and attended GP ≥3 times within 24 months. 37 946 patients were included.ResultsRisk factor and disease testing/monitoring/treatment were assessed as per Australian guidelines (or US guidelines if none available), with guidelines simplified due to limitations in data availability where required. Risk factor assessment in those requiring it: 30% of patients had body mass index and 46% blood pressure within guideline recommended timeframes. Diagnostic testing in at-risk population: 17% had diagnostic testing as per recommendations for CKD and 37% for T2D. Possible undiagnosed disease: Pathology tests indicating possible disease with no diagnosis already coded were present in 6.7% for CKD, 1.6% for T2D and 0.33% familial hypercholesterolaemia. Overall prevalence: Coded diagnoses were recorded in 3.8% for CKD, 6.6% for T2D, 4.2% for ischaemic heart disease, 1% for heart failure, 1.7% for ischaemic stroke, 0.46% for peripheral vascular disease, 0.06% for familial hypercholesterolaemia and 2% for atrial fibrillation. Pharmaceutical prescriptions: the proportion of patients prescribed guideline-recommended medications ranged from 44% (beta blockers for patients with ischaemic heart disease) to 78% (antiplatelets or anticoagulants for patients with ischaemic stroke).ConclusionsUsing GP EMR data, this study identified recorded diagnoses of chronic vascular diseases generally similar to, or higher than, reported national prevalence. It suggested low levels of extractable documented risk factor assessments, diagnostic testing in those at risk and prescription of guideline-recommended pharmacotherapy for some conditions. These baseline data highlight the utility of GP EMR data for potential use in epidemiological studies and by individual practices to guide targeted quality improvement. It also highlighted some of the challenges of using GP EMR data.

APA, Harvard, Vancouver, ISO, and other styles

3

Ward, D. "Treatment of heart diseases." International Journal of Cardiology 42, no. 2 (December 1993): 183–84. http://dx.doi.org/10.1016/0167-5273(93)90091-t.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Zoneraich, Samuel. "Treatment of Heart Diseases." JAMA: The Journal of the American Medical Association 270, no. 17 (November 3, 1993): 2100. http://dx.doi.org/10.1001/jama.1993.03510170090040.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Zbârcea, Cristina Elena, Cristina Daniela Marineci, Oana-Cristina Şeremet, and Simona Negreş. "Pharmacological treatment of ischemic heart diseases." Farmacist.ro 1, no. 186 (2019): 40. http://dx.doi.org/10.26416/farm.186.1.2019.2256.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Falster, Kathleen, Linda Gelgor, Ansari Shaik, Iryna Zablotska, Garrett Prestage, Jeffrey Grierson, Rachel Thorpe, et al. "Trends in antiretroviral treatment use and treatment response in three Australian states in the first decade of combination antiretroviral treatment." Sexual Health 5, no. 2 (2008): 141. http://dx.doi.org/10.1071/sh07082.

Full text

Abstract:

Objectives: To determine if there were any differences in antiretroviral treatment (ART) use across the three eastern states of Australia, New South Wales (NSW), Victoria and Queensland, during the period 1997 to 2006. Methods: We used data from a clinic-based cohort, the Australian HIV Observational Database (AHOD), to determine the proportion of HIV-infected patients on ART in selected clinics in each state and the proportion of treated patients with an undetectable viral load. Data from the national Highly Specialised Drugs program and AHOD were used to estimate total numbers of individuals on ART and the proportion of individuals living with HIV on ART nationally and by state. Data from the HIV Futures Survey and the Gay Community Periodic Survey were used to determine the proportion of community-based men who have sex with men on ART. The proportion of patients with primary HIV infection (PHI) who commenced ART within 1 year of diagnosis was obtained from the Acute Infection and Early Disease Research Program (AIEDRP) CORE01 protocol and Primary HIV and Early Disease Research: Australian Cohort (PHAEDRA) cohorts. Results: We estimated that the numbers of individuals on ART increased from 3181 to 4553 in NSW, 1309 to 1926 in Victoria and 809 to 1615 in Queensland between 2000 and 2006. However, these numbers may reflect a lower proportion of individuals living with HIV on ART in NSW compared with the other states (37% compared with 49 and 55% in 2000). We found similar proportions of HIV-positive men who have sex with men participants were on ART in all three states over the study period in the clinic-based AHOD cohort (81–92%) and two large, community-based surveys in Australia (69–85% and 49–83%). Similar proportions of treated patients had an undetectable viral load across the three states, with a consistently increasing trend over time observed in all states. We found that more PHI patients commenced treatment in the first year following HIV diagnosis in NSW compared with Victoria; however, the sample size was very small. Conclusions: For the most part, patterns of ART use were similar across NSW, Victoria and Queensland using a range of available data from cohort studies, community surveys and national prescription databases in Australia. However, there may be a lower proportion of individuals living with HIV on ART in NSW compared with the other states, and there is some indication of a more aggressive treatment approach with PHI patients in NSW compared with Victoria.

APA, Harvard, Vancouver, ISO, and other styles

7

Jovanovic, Ida, Vojislav Parezanovic, Slobodan Ilic, Djordje Hercog, Milan Vucicevic, Milan Djukic, Irena Vulicevic, et al. "Treatment of cyanotic heart diseases in children." Srpski arhiv za celokupno lekarstvo 132, suppl. 1 (2004): 9–13. http://dx.doi.org/10.2298/sarh04s1009j.

Full text

Abstract:

Cyanotic heart diseases are relatively rare, but they are severe and heterogeneous congenital heart diseases, which require complex surgery. Development of different advanced surgical procedures, such as arterial switch operation (ASO), Fontan and its modifications, Norwood etc. operations, as well as better perioperative care significantly improved survival rate and quality of life of these children. The study group included 308 children treated for cyanotic heart disease in Yugoslavia, in the period January 2000 to July 2004. Some of them (239, 77.6%) were treated at the University Children?s Hospital in Belgrade, and others (69, 22.4%) in different institutions abroad. The age of the operated patients varied between 1 day and 19 years (median 12 months). The patients (pts) were divided into four groups, according to the disease and type of the operation. In the whole group of 308 patients treated due to cyanotic heart disease, there were 232 (75.3%) cases with open heart surgery and 76 (24.7%) with closed procedures. The mortality rate was significantly different between disease/operation groups, and age groups. Average mortality rates differed from 11.8% for palliative procedures to 12.5% for complete corrections. Mortality rate and achieved surgical results in treatment of chil?dren with cyanotic heart diseases were significantly worse than those published by leading cardiac surgery centers in the world. However, there is a clear tendency in introducing new surgical procedures, lowering the age at which the operation is done and decreasing the mortality rates.

APA, Harvard, Vancouver, ISO, and other styles

8

KHAN, HAMZULLAH. "RHEUMATIC HEART DISEASES." Professional Medical Journal 16, no. 01 (March 10, 2009): 100–104. http://dx.doi.org/10.29309/tpmj/2009.16.01.2990.

Full text

Abstract:

O b j e c t i v e s : To determine the frequency of rheumatic heart diseases in a hospital based study in Peshawar. D e s i g n : Across sectional observational. Setting: Cardiology department, Lady-Reading Hospital Peshawar. Period: From July 2005 to July 2006.M e t h o d : Relevant in formations were recorded from patients and treatment chart of the patients, on a questionnaire designed in accordancewith the objectives of the study. Results: A total of 88 patients with established diagnosis of rheumatic hear diseases (RHD) were randomlyselected. Out of total 70.45% were females and 29.54% males, with males to females ratio of 1:2.38. The age range of the patients wasfrom 8 years to 64 years with mean age of 47 years. The mode of age was 35 years. The frequency of rheumatic heart diseases was: MitralStenosis 13.63%, Mitral Regurgitation 60.22%, Mitral Stenosis /Mitral Regurgitation 21.59%, Aortic Stenosis/Aortic Regurgitation 2.27%,Aortic Stenosis 1.13% and Tricuspid Valve Stenosis 1.13%. We observed that RHD were more common in lower social class people(42.04%) with income less than 5000/month. C o n c l u s i o n : In our setup RHD are more common in female gender and especially in theyounger age, Mitral Stenosis was recorded as major type of RHD in our patients.

APA, Harvard, Vancouver, ISO, and other styles

9

Wiewiórka, Łukasz, Jarosław Trębacz, Andrzej Gackowski, Robert Sobczyński, Maciej Stąpór, Janusz Konstanty-Kalandyk, Paweł Kleczyński, Robert Musiał, Bogusław Kapelak, and Jacek Legutko. "Complete transcatheter treatment of multiple heart valve diseases." Kardiologia Polska 79, no. 3 (March 25, 2021): 350–51. http://dx.doi.org/10.33963/kp.15799.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Nakamura, C. "Valvular heart diseases. Surgical treatment of infective endocarditis." Japanese Journal of Cardiovascular Surgery 20, no. 5 (1991): 946–48. http://dx.doi.org/10.4326/jjcvs.20.946.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Ochi, S. "Valvular heart diseases. Surgical treatment of infective endocarditis." Japanese Journal of Cardiovascular Surgery 20, no. 5 (1991): 948–50. http://dx.doi.org/10.4326/jjcvs.20.948.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Medvedev, V. N., Sh M. Kurmaev, G. I. Kharitonov, R. F. Sadekov, and I. I. Vagizov. "Surgical Treatment of Congenital Heart Diseases in Adults." Kazan medical journal 82, no. 3 (June 15, 2001): 161–64. http://dx.doi.org/10.17816/kazmj66499.

Full text

Abstract:

The results of treatment of 701 adult patients with congenital heart diseases from 1987 to 1997 are analyzed. As many as 248 operations with general postoperative lethality 3,2% are made. It is concluded on the necessity of improving the diagnosis of congenital heart diseases in children, especially in rural regions in relation to the high rate of inopportune revealing heart diseases resulting in the increase of the number of inoperable patients with pronounced pulmonary hypertension. The presence of symptoms or pronounced blood escape out of the left article into the right one in the absence of pulmonary hypertension is considered the indication to the radical correction of secondary defect of interatrial septum in adults. The radical heart disease correction in conditions of moderate hypotermy without artificial blood circulation is recommended in small secondary defect of interatrial septum

APA, Harvard, Vancouver, ISO, and other styles

13

Ahmed, Dr Ahmed Mohammed, Abdullah Abdulkhaliq Qazzaz, and Dr Hydair Sachet Khalaf. "Ischemic Heart Disease Treatment." International Journal of Research in Science and Technology 12, no. 01 (2022): 39–41. http://dx.doi.org/10.37648/ijrst.v12i01.005.

Full text

Abstract:

Ischemic heart disease IHD is a rapidly increasing common cause of death in the world. This disease is the insufficient status of oxygen within the cardiac muscles due to an imbalance between oxygen supply and demand, and a cardiac disease that occurs as a result of coronary artery stenosis. Ischemic heart disease diseases are the leading cause of death in both developed and developing countries ,among these IHD is the most prevalent manifestation and is associated with high mortality and morbidity. The clinical presentation of IHD include silent ischaemia, stable angina, unstable angina, myocardial infarction, heart failure and sudden death.

APA, Harvard, Vancouver, ISO, and other styles

14

MALIK, GULZAR AHMAD, KASHIF KURSHID QURESHI, IMTIAZ AHMAD, and Muhammad Afzal. "PERIPHERAL VASCULAR DISEASES." Professional Medical Journal 14, no. 01 (March 10, 2007): 134–44. http://dx.doi.org/10.29309/tpmj/2007.14.01.3640.

Full text

Abstract:

Objectives: To observe the prevalence & presentation and to review the noninvasive approaches for the evaluation and treatment of patients presenting with peripheral vascular diseases at Bahawal Victoria Hospital Bahawalpur. Design: Prospective randomized study. Place and Duration: This study was conducted from July 2003 to June 2005 at the department of Surgery Bahawal Victoria Hospital Bahawalpur. Patients & Methods: Twenty patients, 2 females and 18 males admitted with peripheral vascular diseases (PVD) fulfilling the inclusion criteria were evaluated and treated medically and surgically. A standard noninvasive approach for the evaluation of these patients was adopted by history & thorough clinical examination, Doppler USG of the vessels, Ankle Brachial Indices (ABI), Duplex Scanning and MRI in a few cases. Results: The relative frequency of PVD at BVH Bahawalpur was 1.2%. The majority of patients (60%) were in the 4th decade of life and male (90%). The smoking was exclusively the major predisposing risk factor (90%). The common (90%) presentation of patients was intermittent claudication with 60% gangrenous disease with an average duration of 4years, The lower limbs were involved in 90% cases with 70% bilateral disease. Majority (90%) of the patients was diagnosed clinically and the objective severity of the disease was assessed with Doppler sonography in all the patients. The ABI was <0.5 in 85% cases. The duplex scanning was needed only in 10% patients. The treatment procedures carried out were primary amputation in 45% followed by conservative on medicines 20%, atherectomy in 15%, lumbar sympathectomy in 10% and resection or repair of pseudoaneurysms in 10% of cases. The ultimate rate of amputation at various levels was seen to be 75%. Conclusion: The prevalence of PVD is rapidly increasing in our society which is causing a horrible threat in the form of physical disabilities at a younger age group of poor class mostly. Smoking remains exclusively the only major risk factor. Much time and money can be saved by evaluating and treating these patients by noninvasive approaches but prevention is the besttherapeutic strategy achieving by abstinence from the smoking.

APA, Harvard, Vancouver, ISO, and other styles

15

Henning, Robert J. "Recognition and treatment of ischemic heart diseases in women." Future Cardiology 15, no. 3 (May 2019): 197–225. http://dx.doi.org/10.2217/fca-2018-0079.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Shimono, T. "Valvular heart diseases. Surgical treatment of prosthetic valve endocarditis." Japanese Journal of Cardiovascular Surgery 20, no. 5 (1991): 955–57. http://dx.doi.org/10.4326/jjcvs.20.955.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Koyanagi, H. "Congenital heart diseases (1). Surgical treatment of vascular rings." Japanese Journal of Cardiovascular Surgery 18, no. 1 (1988): 57–59. http://dx.doi.org/10.4326/jjcvs.18.57.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Bilgimol, Joseph C. "Stem cells: An eventual treatment option for heart diseases." World Journal of Stem Cells 7, no. 8 (2015): 1118. http://dx.doi.org/10.4252/wjsc.v7.i8.1118.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Mirolyubov, L. M., D. Yu Petrushenko, J. B. Kalinicheva, and D. R. Sabirova. "Diagnostics and treatment of congenital heart diseases in newborns." Kazan medical journal 96, no. 4 (August 15, 2015): 628–32. http://dx.doi.org/10.17750/kmj2015-628.

Full text

Abstract:

Aim. Early detection and timely appropriate surgical treatment of congenital heart disease in order to reduce infant mortality. Methods. The algorithm was designed for the prediction of critical conditions in congenital heart disease in newborns. The algorithm is simple to use, because it does not set a pediatrician-neonatologist a difficult task for the accurate diagnosis of congenital heart disease, but leads physician from the syndromic diagnosis to a certain group of diseases and, therefore, appropriate strategy of patient treatment and management. The algorithm combines both syndromes and hemodynamic conditions causing them. The conditions are divided into fetal-dependent and fetal-independent, which determines the time of surgery. The questionnaire consisting of a series of questions with multiple choice answers helps the doctor to see into the symptoms and syndromes. The questions are made in a way to emphasize the certain signs, the details of medical history and disease progression to pediatricians. It is important to notice that 13 out of 20 questions are based on the medical history and clinical picture, 7 questions are based on the test results such as electrocardiography, radiography, and do not include echocardiography. Results. Since 2000, the questionnaire was implemented in the Republic of Tatarstan as a recommended diagnostic algorithm for examining newborns with congenital heart disease. Since 2003, the questionnaire and algorithm for prediction of the critical conditions was introduced by the order №867 of the Ministry of Health of the Republic of Tatarstan «On measures to improve health care in congenital heart disease in children». Remote consultations with maternity hospitals are strictly based on them. They carry a certain training load, and when doctors pronounce aloud all the items of the test, the examination algorithm gradually becomes automatic. Conclusion. During 13 years of using the proposed diagnostic algorithm for congenital heart disease with physiological rationale for palliative care and timely terms of surgery, the mortality rate from congenital heart disease in the Republic of Tatarstan has significantly dropped.

APA, Harvard, Vancouver, ISO, and other styles

20

Kovacicova, K., N. Omran, and J. Mandak. "Combined surgical treatment of lung cancer and heart diseases." Bratislava Medical Journal 115, no. 12 (2014): 776–80. http://dx.doi.org/10.4149/bll_2014_150.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Dinarević, Senka, Fedzat Jonuzi, Mirza Halimic, Zijo Begic, Almira Kadić, and Refet Gojak. "LEVOSIMENDAN IN TREATMENT OF CONGENITAL AND ACQUIRED HEART DISEASES." Archives of Disease in Childhood 101, no. 1 (December 14, 2015): e1.32-e1. http://dx.doi.org/10.1136/archdischild-2015-310148.38.

Full text

Abstract:

IntroductionLevosimendan as a new generation vasoactive coronary and peripheral dilatation drug, has been recently developed for cardiac decompensation treatment.AimTo evaluate the effects on cardiac function during treatment with Levosimendan in cardiac decompensated severely ill infants and children.MethodsRetrospective-prospective study was performed in Paediatric Clinic CC University of Sarajevo, from 01.01.2013. till 30.12.2014. Study included 7 pts; with congenital/post surgery Tetralogia Fallot/ and acquired heart diseases/dilated cardiomyopathy-myocarditis/pts. Patients were divided into two groups: I Group pre treatment and II Group, post Levosimendan treatment. Parameters evaluated were: age, sex, diagnosis, left ventricle EF /LV EF/pre and post-treatment (EF1 and EF2/and use of inotropic drugs.ResultsThe evaluated variables were: age in I Group of pts /4/ with congenital heart disease: mean 7.5 months/ratio: 6.5–8.5 months of age/and in second with acquired heart diseases /3/, mean: 8.5 years of age/3–14 years/, 3 boys; inotropic drugs used in both Groups of pts: Noradrenalin, Dobutamin, Dopamine and Corotrop which were decreased and stopped in the First Group 2nd day post Levosimendan start and in second Group, 3rd day stopped post Levosimendan start. LV EF evaluated in both Groups; difference of mean EF1 in relation to mean EF2 values, showed statistically significant improvement of LV function /p=0,002/ and decrease in inotropic support.ConclusionLevosimendan has positive effects on myocardial function restoration regardless on congenital or acquired heart diseases in paediatric population as well as in decrease in inotropic support and rapid myocardial cell recovery.

APA, Harvard, Vancouver, ISO, and other styles

22

Lockhart, Peter B., Michael T. Brennan, William H. Cook, Howell Sasser, Roger D. Lovell, Eric R. Skipper, Jenene Noll, Timothy L. Cox, Deborah J. Aten, and Joseph W. Cook. "Concomitant surgical treatment of dental and valvular heart diseases." Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 107, no. 1 (January 2009): 71–76. http://dx.doi.org/10.1016/j.tripleo.2008.09.014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Vignati, Gabriele, Giancarlo Crupi, Vittorio Vanini, Fiore S. Iorio, Adele Borghi, and Sandra Giusti. "Surgical treatment of arrhythmias related to congenital heart diseases." Annals of Thoracic Surgery 75, no. 4 (April 2003): 1194–99. http://dx.doi.org/10.1016/s0003-4975(02)04653-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Nakamura, Kazufumi. "Treatment for pulmonary hypertension due to left heart diseases." Hypertension Research 39, no. 1 (November 5, 2015): 6–7. http://dx.doi.org/10.1038/hr.2015.116.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Gupta, Purnima, Evelyn Garcia, Amrita Sarkar, Sumit Kapoor, Khadija Rafiq, Hitendra S. Chand, and Rahul Dev Jayant. "Nanoparticle Based Treatment for Cardiovascular Diseases." Cardiovascular & Hematological Disorders-Drug Targets 19, no. 1 (January 28, 2019): 33–44. http://dx.doi.org/10.2174/1871529x18666180508113253.

Full text

Abstract:

Nanotechnology has gained increased attention for delivering therapeutic agents effectively to the cardiovascular system. Heart targeted nanocarrier based drug delivery is a new, effective and efficacious approach for treating various cardiac related disorders such as atherosclerosis, hypertension, and myocardial infarction. Nanocarrier based drug delivery system circumvents the problems associated with conventional drug delivery systems, including their nonspecificity, severe side effects and damage to the normal cells. Modification of physicochemical properties of nanocarriers such as size, shape and surface modifications can immensely alter its invivo pharmacokinetic and pharmacodynamic data and will provide better treatment strategy. Several nanocarriers such as lipid, phospholipid nanoparticles have been developed for delivering drugs to the target sites within the heart. This review summarizes and increases the understanding of the advanced nanosized drug delivery systems for treating cardiovascular disorders with the promising use of nanotechnology.

APA, Harvard, Vancouver, ISO, and other styles

26

Kovalev, Dmitriy Sergeevich. "Clinical picture, diagnosis and treatment of mitral valvular diseases." Spravočnik vrača obŝej praktiki (Journal of Family Medicine), no. 3 (March 1, 2021): 8–19. http://dx.doi.org/10.33920/med-10-2103-01.

Full text

Abstract:

Heart defects are pathological changes in the heart, during which the defects of the valve apparatus or its walls are observed, leading to heart failure. There are two large groups of heart defects: congenital and acquired. The diseases are chronic, slowly progressing; therapy only alleviates their course, but does not eliminate the cause of their occurrence; full recovery is possible only with surgical intervention. This article is devoted to the issues of classification, etiology, pathogenesis, clinical symptoms, approaches to the diagnosis and treatment of mitral valvular diseases.

APA, Harvard, Vancouver, ISO, and other styles

27

Kaczmarek, Krzysztof, Iwona Cygankiewicz, Paweł Ptaszyński, Barbara Cyranik, and Jerzy Krzysztof Wranicz. "Heart rhythm disturbances in infectious diseases." In a good rythm 4, no. 45 (December 29, 2017): 10–12. http://dx.doi.org/10.5604/01.3001.0010.7490.

Full text

Abstract:

An effort for seeking a cause of arrhythmia is recommended in guidelines for practice. An infectious etiology is found in some patients with arrhythmias, which can influence on further therapy. This paper indicate that infectious etiology ought to be taken into consideration in diagnostic and treatment process in patients with arrhythmias.

APA, Harvard, Vancouver, ISO, and other styles

28

Dale, K., E. Tay, J. M. Trauer, P. Trevan, and J. Denholm. "Gender differences in tuberculosis diagnosis, treatment and outcomes in Victoria, Australia, 2002–2015." International Journal of Tuberculosis and Lung Disease 21, no. 12 (December 1, 2017): 1264–71. http://dx.doi.org/10.5588/ijtld.17.0338.

Full text

Abstract:

BACKGROUND: Gender has a significant impact on tuberculosis (TB) diagnosis and outcomes in many settings worldwide. We explored gender differences in Victoria, Australia, a low-incidence setting.METHODS: Retrospective cohort study: 2002–2015. Gender was included as an independent variable in multivariate statistical analyses assessing TB management.RESULTS: There were 2655 (54.5%) males and 2212 (45.5%) females notified (male:female ratio = 1.2:1). Among cases with pulmonary involvement, males underwent a chest X-ray or CT scan (CXR) sooner (hazard ratio [HR] 1.2, 95%CI 1.04–1.31, P = 0.010), began treatment sooner after presentation (HR 1.2, 95%CI 1.08–1.34, P = 0.001) and were more likely to have a sputum smear sample performed (OR 1.3, 95%CI 1.01–1.55, P = 0.037). Male cases with extra-pulmonary TB sought health care sooner after symptom onset (HR 1.3, 95%CI 1.03–1.58, P = 0.024) and were more likely to have an abnormal CXR (OR 1.9, 95%CI 1.54–2.32, P < 0.001). Males were more likely to die before or during treatment (OR 1.5, 95%CI 1.06–2.11, P = 0.024).CONCLUSIONS: Women experienced small delays in management compared with men, with no obvious detriment to assessment results or treatment outcomes. Differences were consistent with the hypothesis that males manifest more severe disease at presentation, which could be related to a range of biological and social factors.

APA, Harvard, Vancouver, ISO, and other styles

29

Li, Dan, Wei Liu, Dan Ma, Fengxiang Yun, Shu Li, and Fengqi Liu. "An Effective Treatment for Heart Failure Caused by Valvular Heart Diseases: Thoracic Sympathetic Block." Journal of Investigative Surgery 31, no. 3 (February 27, 2017): 236–40. http://dx.doi.org/10.1080/08941939.2017.1284965.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Evseev, E. P., E. V. Balakin, Ya A. Aidamirov, E. V. Ivanova, D. A. Kondratiev, V. A. Ivanov, and Yu V. Belov. "Surgical treatment of heart diseases through the right-sided minithoracotomy." Kardiologiya i serdechno-sosudistaya khirurgiya 14, no. 1 (2021): 26. http://dx.doi.org/10.17116/kardio20211401126.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Haruta, Y. "Surgical treatment of congenital heart diseases with complication of malformation." Japanese Journal of Cardiovascular Surgery 18, no. 4 (1989): 613–15. http://dx.doi.org/10.4326/jjcvs.18.613.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Ohtake, H. "Surgical treatment for WPW syndrome combined with congenital heart diseases." Japanese Journal of Cardiovascular Surgery 19, no. 3 (1989): 567–69. http://dx.doi.org/10.4326/jjcvs.19.567.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Senda, H. "Valvular heart diseases. (2). Surgical treatment after percutaneal transseptal valvuloplasty." Japanese Journal of Cardiovascular Surgery 19, no. 4 (1990): 691–93. http://dx.doi.org/10.4326/jjcvs.19.691.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Palatini, Paolo. "Elevated Heart Rate in Cardiovascular Diseases: A Target for Treatment?" Progress in Cardiovascular Diseases 52, no. 1 (July 2009): 46–60. http://dx.doi.org/10.1016/j.pcad.2009.05.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Kubler, W. "Treatment of cardiac diseases: evidence based or experience based medicine?" Heart 84, no. 2 (August 1, 2000): 134–36. http://dx.doi.org/10.1136/heart.84.2.134.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Beis, Dimitris, Inga Zerr, Fabio Martelli, Wolfram Doehner, and Yvan Devaux. "RNAs in Brain and Heart Diseases." International Journal of Molecular Sciences 21, no. 10 (May 25, 2020): 3717. http://dx.doi.org/10.3390/ijms21103717.

Full text

Abstract:

In the era of single-cell analysis, one always has to keep in mind the systemic nature of various diseases and how these diseases could be optimally studied. Comorbidities of the heart in neurological diseases as well as of the brain in cardiovascular diseases are prevalent, but how interactions in the brain–heart axis affect disease development and progression has been poorly addressed. Several brain and heart diseases share common risk factors. A better understanding of the brain–heart interactions will provide better insights for future treatment and personalization of healthcare, for heart failure patients’ benefit notably. We review here emerging evidence that studying noncoding RNAs in the brain–heart axis could be pivotal in understanding these interactions. We also introduce the Special Issue of the International Journal of Molecular Sciences RNAs in Brain and Heart Diseases—EU-CardioRNA COST Action.

APA, Harvard, Vancouver, ISO, and other styles

37

Khalequzzaman, Md, M. A. Islam, Md O. Hoque, M. Ferdous, A. H. K. Chowdhury, Md M. Rahman, and K. K. Karmakar. "Myonecrosis in Aortic Valvular Heart Diseases." Journal of Medical Science & Research 13, Number 2 (July 1, 2009): 9–12. http://dx.doi.org/10.47648/jmsr.2009.v1302.02.

Full text

Abstract:

This cross sectional study was done among 20 patients with aortic stenosis and 20 healthy controls to evaluate the association of cardiac specific troponin 1 (ant) and sonic valvular heart diseases. The study was conducted in °militant, department in National laminae of Cardiovascular Diseases (N1CVD.)A structured queslionilaire and checklist was used to collect data through face to face interview. Color dapple, echocarchiognsphy was done and 5 ml of venous sample was dmwo from each subjects and laboratory estimation of an, was done. The arid in control group and sonic stenosis patients showed significant difference in mean (<0.001). ant level in aortic stenosis patients increases in the absence of heart failure indicating that it can expose the cardiotnyocnes to injury prior to development of oven left ventricular dysftinction. So. serial monitoring of aid may help clinicians to give definitive treatment (reface development af complications.

APA, Harvard, Vancouver, ISO, and other styles

38

Okamura, T. "Valvular heart diseases. (4). Surgical treatment of calcific aortic stenosis combined with ischemic heart disease." Japanese Journal of Cardiovascular Surgery 19, no. 4 (1990): 715–16. http://dx.doi.org/10.4326/jjcvs.19.715.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Rahman, Zaheedur, Md Fakhrul Alam, and Israt Jahan. "Association of Hypertension and Coronary Heart Diseases." KYAMC Journal 12, no. 1 (May 8, 2021): 44–47. http://dx.doi.org/10.3329/kyamcj.v12i1.53368.

Full text

Abstract:

Background: Hypertension is one and the major non-transferable diseases in the world and contributing altogether to the burden of cardiovascular diseases, stroke, kidney failure, and premature death. The association of hypertension and coronary heart disease is a very frequent one. Just 11% of the total instances of hypertension have compelling control of circulatory strain. Objective: The main goal of this study is to assess the association between hypertension and coronary heart diseases. Materials and Methods:A prospective observational study was conducted in a total of 300 patients from January 2016 to July 2016 in a single institution (Private hospital) in Dhaka, Bangladesh. The incidence of hypertension, its control, and association with coronary heart diseases was analysed in the patients. Results: In our investigation, the outcomes demonstrated that hypertension is highly associated with cardiovascular diseases in patients above 50 years old (p=0.001). A total of 228 patients in the study had hypertension and 30 were recently recognized. 63% of the patients with hypertension have viable control of blood pressure with medications and systolic hypertension was revealed in 6% cases. Conclusion: Hypertension and its treatment are related to coronary heart diseases. Treatment should be meant to achieve optimal values of blood pressure, and all the methodologies to treat coronary heart diseases should be considered on an individual premise. KYAMC Journal.2021;12(1): 44-47

APA, Harvard, Vancouver, ISO, and other styles

40

Podzolkov, V. P., V. B. Samsonov, M. R. Chiaureli, I. V. Kokshenev, B. N. Sabirov, T. Yu Danilov, D. V. Kovalev, and M. A. Saidov. "Congenital heart valve diseases: modern approaches to diagnosis and surgical treatment." Bulletin of Bakoulev Center "Cardiovascular Diseases" 18, no. 3 (2017): 271–77. http://dx.doi.org/10.24022/1810-0694-2017-18-3-271-277.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Saga, T. "Congenital heart diseases (1). Surgical treatment for pediatric coronary artery disease." Japanese Journal of Cardiovascular Surgery 18, no. 1 (1988): 47–49. http://dx.doi.org/10.4326/jjcvs.18.47.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Tedoriya, T. "Surgical treatment for ischemic heart disease with other arteriosclerotic vascular diseases." Japanese Journal of Cardiovascular Surgery 19, no. 5 (1990): 953–54. http://dx.doi.org/10.4326/jjcvs.19.953.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Cinteza, Eliza Elena, Alin Marcel Nicolescu, Cristina Filip, Georgiana Nicolae, Gabriela Duica, Cosmin Alexandru Grigore, and Hyam Mahmoud. "Interventional Treatment of Cardiac Emergencies in Children with Congenital Heart Diseases." Journal Of Cardiovascular Emergencies 5, no. 1 (March 1, 2019): 7–17. http://dx.doi.org/10.2478/jce-2019-0002.

Full text

Abstract:

Abstract Cardiac emergencies in children represent an extremely important issue in medical practice. In general, interventional treatment could be optional in many situations, however it can be indicated in emergency conditions. There are many diseases at pediatric age that can benefit from interventional treatment, thus reducing the surgical risks and subsequent complications. Balloon atrioseptostomy, patent ductus arteriosus (PDA) closure, percutaneous or hybrid closure of a ventricular septal defect, pulmonary or aortic valvuloplasty, balloon angioplasty for aortic coarctation, implantation of a stent for coarctation of the aorta, for severe stenosis of the infundibulum of the right ventricle, or for PDA correction are among the procedures that can be performed in emergency situations. This review aims to present the current state of the art in the field of pediatric interventional cardiology.

APA, Harvard, Vancouver, ISO, and other styles

44

Lassner, Dirk, Christine S. Siegismund, Jenny Stehr, Maria Rohde, Felicitas Escher, Carsten Tschöpe, Ulrich Michael Gross, Uwe Kühl, and Heinz-Peter Schultheiss. "Recent Advances in Molecular Diagnostics and Treatment of Heart Muscle Diseases." Journal of Analytical Sciences, Methods and Instrumentation 03, no. 02 (2013): 98–109. http://dx.doi.org/10.4236/jasmi.2013.32012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Habal, Petr, Jiří Šimek, Vladimír Lonský, and Josef Novotný. "Possibilities of Combined Surgical Treatment of Lung Tumours and Heart Diseases." Acta Medica (Hradec Kralove, Czech Republic) 49, no. 3 (2006): 175–81. http://dx.doi.org/10.14712/18059694.2017.128.

Full text

Abstract:

The purpose of the study was a retrospective evaluation of the outcome of surgical therapy of lung cancer in patients where there was concomitant cardiac disease and who underwent a cardiac operation either because of ischemic heart disease or because of valvular disease. These patients were operated on at various time intervals (two to ten months) after their cardiac operation. Some patients had their lung cancer surgery after the cardiac operation because of the high risk of possible cardiac postoperative complications; in one patient the lung operation preceded the cardiac one.

APA, Harvard, Vancouver, ISO, and other styles

46

Kawasumi, Hisashi, Naoya Satoh, Yuji Abe, Akihiro Narimatsu, and Yoshimi Kitada. "MCC-135, a new agent for the treatment of heart diseases." Japanese Journal of Pharmacology 76 (1998): 277. http://dx.doi.org/10.1016/s0021-5198(19)41219-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Li, Shengwen Calvin, Lang Wang, Hong Jiang, Julyana Acevedo, Anthony Christopher Chang, and William Gunter Loudon. "Stem cell engineering for treatment of heart diseases: Potentials and challenges." Cell Biology International 33, no. 3 (March 2009): 255–67. http://dx.doi.org/10.1016/j.cellbi.2008.11.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Irwin, R., A. Surapaneni, D. Smith, J. Schmidt, H. Rigby, and S. R. Smith. "Verification of an alternative sludge treatment process for pathogen reduction at two wastewater treatment plants in Victoria, Australia." Journal of Water and Health 15, no. 4 (May 26, 2017): 626–37. http://dx.doi.org/10.2166/wh.2017.316.

Full text

Abstract:

At South East Water wastewater treatment plants (WwTPs) in Victoria, Australia, biosolids are stockpiled for three years in compliance with the State guidelines to achieve the highest pathogen reduction grade (T1), suitable for unrestricted use in agriculture and landscaping. However, extended stockpiling is costly, may increase odour nuisance and greenhouse gas emissions, and reduces the fertiliser value of the biosolids. A verification programme of sampling and analysis for enteric pathogens was conducted at two WwTPs where sludge is treated by aerobic and anaerobic digestion, air drying (in drying pans or solar drying sheds) and stockpiling, to enumerate and, if present, monitor the decay of a range of enteric pathogens and parasites. The sludge treatment processes at both WwTPs achieved T1 grade biosolids with respect to prescribed pathogenic bacterial numbers (<1 Salmonella spp. 50 g−1 dry solids (DS) and <100 Escherichia coli g−1 DS) and >3 log10 enteric virus reduction after a storage period of one year. No Ascaris eggs were detected in the influent to the WwTPs, confirming previous studies that the presence of helminth infections in Victoria is extremely low and that Ascaris is not applicable as a control criterion for the microbiological quality of biosolids in the region.

APA, Harvard, Vancouver, ISO, and other styles

49

Magadum, Ajit. "Modified mRNA Therapeutics for Heart Diseases." International Journal of Molecular Sciences 23, no. 24 (December 8, 2022): 15514. http://dx.doi.org/10.3390/ijms232415514.

Full text

Abstract:

Cardiovascular diseases (CVD) remain a substantial global health problem and the leading cause of death worldwide. Although many conventional small-molecule treatments are available to support the cardiac function of the patient with CVD, they are not effective as a cure. Among potential targets for gene therapy are severe cardiac and peripheral ischemia, heart failure, vein graft failure, and some forms of dyslipidemias. In the last three decades, multiple gene therapy tools have been used for heart diseases caused by proteins, plasmids, adenovirus, and adeno-associated viruses (AAV), but these remain as unmet clinical needs. These gene therapy methods are ineffective due to poor and uncontrolled gene expression, low stability, immunogenicity, and transfection efficiency. The synthetic modified mRNA (modRNA) presents a novel gene therapy approach which provides a transient, stable, safe, non-immunogenic, controlled mRNA delivery to the heart tissue without any risk of genomic integration, and achieves a therapeutic effect in different organs, including the heart. The mRNA translation starts in minutes, and remains stable for 8–10 days (pulse-like kinetics). The pulse-like expression of modRNA in the heart induces cardiac repair, cardiomyocyte proliferation and survival, and inhibits cardiomyocyte apoptosis post-myocardial infarction (MI). Cell-specific (cardiomyocyte) modRNA translation developments established cell-specific modRNA therapeutics for heart diseases. With these laudable characteristics, combined with its expression kinetics in the heart, modRNA has become an attractive therapeutic for the treatment of CVD. This review discusses new developments in modRNA therapy for heart diseases.

APA, Harvard, Vancouver, ISO, and other styles

50

Kobalava, Zh D., and P. V. Lazarev. "Nitric oxide — soluble guanylate cyclase — cyclic guanosine monophosphate signaling pathway in the pathogenesis of heart failure and search for novel therapeutic targets." Cardiovascular Therapy and Prevention 20, no. 6 (October 16, 2021): 3035. http://dx.doi.org/10.15829/1728-8800-2021-3035.

Full text

Abstract:

Heart failure is a severe disease with an unfavorable prognosis, which requires intensification of therapy and the search for novel approaches to treatment. In this review, the physiological significance of soluble guanylate cyclase-related signaling pathway, reasons for decrease in its activity in heart failure and possible consequences are discussed. Pharmacological methods of stimulating the production of cyclic guanosine monophosphate using drugs with different mechanisms of action are considered. Data from clinical studies regarding their effectiveness and safety are presented. A promising approach is stimulation of soluble guanylate cyclase, which showed beneficial effects in preclinical studies, as well as in the recently completed phase III VICTORIA study.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!